These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 25175857)
1. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer. Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857 [TBL] [Abstract][Full Text] [Related]
2. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680 [TBL] [Abstract][Full Text] [Related]
3. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines. Muñoz M; González-Ortega A; Coveñas R Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581 [TBL] [Abstract][Full Text] [Related]
4. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605 [TBL] [Abstract][Full Text] [Related]
5. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. Munoz M; Covenas R; Esteban F; Redondo M J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269 [TBL] [Abstract][Full Text] [Related]
6. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Muñoz M; Rosso M; Robles-Frias MJ; Salinas-Martín MV; Rosso R; González-Ortega A; Coveñas R Lab Invest; 2010 Aug; 90(8):1259-69. PubMed ID: 20458280 [TBL] [Abstract][Full Text] [Related]
7. Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor. González-Ortega A; Sánchez-Vaderrábanos E; Ramiro-Fuentes S; Salinas-Martín MV; Carranza A; Coveñas R; Muñoz M Peptides; 2014 May; 55():1-12. PubMed ID: 24548567 [TBL] [Abstract][Full Text] [Related]
8. Involvement of substance P and the NK-1 receptor in cancer progression. Muñoz M; Coveñas R Peptides; 2013 Oct; 48():1-9. PubMed ID: 23933301 [TBL] [Abstract][Full Text] [Related]
9. Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer. Zhou Y; Zhao L; Xiong T; Chen X; Zhang Y; Yu M; Yang J; Yao Z Breast Cancer Res Treat; 2013 Jul; 140(1):49-61. PubMed ID: 23807418 [TBL] [Abstract][Full Text] [Related]
10. NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Muñoz M; Rosso M; Aguilar FJ; González-Moles MA; Redondo M; Esteban F Invest New Drugs; 2008 Apr; 26(2):111-8. PubMed ID: 17906845 [TBL] [Abstract][Full Text] [Related]
11. Cancer progression and substance P. Coveñas R; Muñoz M Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838 [TBL] [Abstract][Full Text] [Related]
12. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Rosso M; Robles-Frías MJ; Coveñas R; Salinas-Martín MV; Muñoz M Tumour Biol; 2008; 29(4):245-54. PubMed ID: 18781096 [TBL] [Abstract][Full Text] [Related]
13. The antiproliferative action of [D-Arg(1), D-Phe(5), D-Trp(7,9), LEU(11)] substance P analogue antagonist against small-cell- and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist. Munoz M; Recio S; Rosso M; Redondo M; Covenas R J Physiol Pharmacol; 2015 Jun; 66(3):421-6. PubMed ID: 26084224 [TBL] [Abstract][Full Text] [Related]
14. Neurokinin-1 receptor: a new promising target in the treatment of cancer. Muñoz M; Coveñas R Discov Med; 2010 Oct; 10(53):305-13. PubMed ID: 21034671 [TBL] [Abstract][Full Text] [Related]
15. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011. Muñoz M; Martinez-Armesto J; Coveñas R Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287 [TBL] [Abstract][Full Text] [Related]
16. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant. Coveñas R; Rodríguez FD; Robinson P; Muñoz M Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914 [TBL] [Abstract][Full Text] [Related]
17. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines. Muñoz M; Rosso M; Coveñas R Pharmacol Rep; 2017 Aug; 69(4):696-701. PubMed ID: 28550801 [TBL] [Abstract][Full Text] [Related]
18. Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138. Muñoz M; Rosso M; Coveñas R; Montero I; González-Moles MA; Robles MJ Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2775-81. PubMed ID: 17525212 [TBL] [Abstract][Full Text] [Related]
19. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Muñoz M; Rosso M Invest New Drugs; 2010 Apr; 28(2):187-93. PubMed ID: 19148578 [TBL] [Abstract][Full Text] [Related]
20. The NK-1 receptor: a new target in cancer therapy. Muñoz M; Rosso M; Coveñas R Curr Drug Targets; 2011 Jun; 12(6):909-21. PubMed ID: 21226668 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]